Show simple item record

dc.contributor.authorMorgan, Robert David
dc.contributor.authorStamatopoulou, Sofia
dc.contributor.authorMescallado, Nerissa
dc.contributor.authorSaunders, Geoff
dc.contributor.authorWelch, Richard
dc.contributor.authorMitchell, Claire L
dc.contributor.authorHasan, Jurjees
dc.contributor.authorClamp, Andrew R
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2019-06-04T09:44:28Z
dc.date.available2019-06-04T09:44:28Z
dc.date.issued2019en
dc.identifier.citationMorgan RD, Stamatopoulou S, Mescallado N, Saunders G, Welch R, Mitchell C, et al. Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer. ESMO Open. 2019; 4(2):e000463.en
dc.identifier.pmid30962962en
dc.identifier.doi10.1136/esmoopen-2018-000463en
dc.identifier.urihttp://hdl.handle.net/10541/621828
dc.description.abstractBackground: Malignant bowel obstruction (MBO) is a common cause of morbidity and mortality in women diagnosed with ovarian cancer. Earlier detection of MBO may improve patient outcomes. There are currently no screening tools to assist detection. Aim: We report a screening questionnaire that can be used to detect MBO, and how the severity score for key clinical symptoms correlate with radiological evidence of MBO from ovarian cancer. Design: A case-control study in which patients with relapsed, metastatic ovarian cancer were asked to answer 10 questions related to key clinical symptoms associated with intestinal obstruction. The study group included women with CT-confirmed MBO, whereas the control group had no evidence of MBO. Patients scored each question according to severity from 1 (least severe) to 5 (most severe). Setting/participants: Between 1 June and 31 December 2016, 37 women completed the screening questionnaire. Results: Patients in the study group (n=17) reported significantly higher (ie, more severe) scores for abdominal pain, nausea, vomiting and constipation. In contrast, differences in severity scores between groups did not differ significantly in response to questions regarding abdominal swelling, borborygmi, diarrhoea or loss of appetite. All patients in the study group more frequently stated that their symptoms had deteriorated within the 2 months prior to completing the questionnaire. Conclusion: Here we report the key clinical symptoms associated with radiologically-confirmed MBO in relapsed, metastatic ovarian cancer. We recommend healthcare practitioners focus on these specific symptoms during patient consultations in order to improve risk stratification of MBO.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1136/esmoopen-2018-000463en
dc.titleScreening tool for malignant bowel obstruction in relapsed, metastatic ovarian canceren
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalESMO Openen
refterms.dateFOA2019-06-06T11:19:36Z


Files in this item

Thumbnail
Name:
e000463.full.pdf
Size:
537.5Kb
Format:
PDF
Description:
Full text, Open Access article

This item appears in the following Collection(s)

Show simple item record